Drug Database
IN

influenza vaccine (Inflexal V / Invivac / Inflexal Berna)

✓ Approved

Johnson & Johnson Services, Inc. · 疫苗 · 疫苗

什么是 influenza vaccine?

influenza vaccine 是一种疫苗,由Johnson & Johnson Services, Inc.研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intramuscular (IM) Injection、Subcutaneous Injection。

药物档案

商品名Inflexal V, Invivac, Inflexal Berna
公司Johnson & Johnson Services, Inc.
药物类别疫苗, 大分子
给药途径Injectable (Others), Intramuscular (IM) Injection, Subcutaneous Injection
状态Approved

相关研究文献

PubMedFrontiers in public health2026-11-18

Characteristics of adverse events of inactivated quadrivalent influenza vaccine in healthy populations: a meta-analysis based on randomized controlled trials.

Kang Liuyang L, Yang Jing J, Cheng Jingru J, Tang Shaowen S et al.

Influenza constitutes a critical global public health issue, and quadrivalent inactivated influenza vaccine (QIV) is widely used, yet systematic analyses of its adverse events (AEs) remain lacking. This meta-analysis aimed to characterize AEs following QIV vaccination in healthy populations. We searched for randomized controlled trials (RCTs) of QIV vaccination in healthy populations, extracted AE data from QIV groups, pooled incidence rates, and compared the risks of AEs between QIV and trivalent influenza vaccine (TIV) using a random-effects model. Subgroup analyses, meta-regression, and sensitivity analyses were applied to explore heterogeneity and result robustness. Publication bias was evaluated utilizing Begg's and Egger's tests. A total of 29 studies published from 2008 to 2025 were included, involving 28,410 participants with 8,197 reported AEs in total. The overall incidence of AEs after QIV vaccination in healthy populations was 43% (95% CI: 31%-54%), with an incidence of 27% (95% CI: 18%-37%) for local AEs and 20% (95% CI: 14%-26%) for systemic AEs. The incidence of SAEs was 0.96%. The QIV group showed significantly elevated risks of overall and local AEs relative to TIV (P < 0.05), while no significant differences were detected in systemic AEs and SAEs between the two groups (P > 0.05). Heterogeneity was associated with study period, study region, AE collection duration, and vaccine origin. Sensitivity analyses and publication bias analyses confirmed result stability. This study summarizes AE incidence and features after QIV in healthy populations, supporting clinical vaccination and post-vaccination safety surveillance with exploratory data. https://www.crd.york.ac.uk/PROSPERO/view/CRD420251233388, identifier CRD420251233388.

PMID 43047547
阅读全文 →
PubMedBMJ public health2026-11-18

Decomposition of disparities in influenza and pneumococcal vaccination coverage by immigrant status among older adults in Canada: results from the Canadian longitudinal study on aging (CLSA).

Kim Ji Yoon JY, Yang Seungmi S, Russell W Alton WA, Sulis Giorgia G et al.

Immigrant older adults in Canada have lower coverage for influenza and pneumococcal vaccinations compared with non-immigrants, yet the specific factors contributing to these disparities remain underexplored. Using data from the Canadian Longitudinal Study on Aging, we applied a non-linear Blinder-Oaxaca decomposition method to assess the contributions of demographic, socioeconomic, health-related and neighbourhood characteristics to influenza (n=23 214) and pneumococcal (n=22 235) vaccination disparities. Overall, the disparities were driven by differences in associations between characteristics and vaccination outcomes (ie, coefficient estimates), rather than by differences in distributions of characteristics (ie, covariate estimates). Some characteristics contributed to widening and others to narrowing disparities but the contributions varied by vaccine type. The combined contributions of all covariates were negative (influenza: -1.95 (95% CI -2.80 to -1.11); pneumococcal: -0.24 (95% CI -1.15 to 0.67)) suggesting that if immigrants had the same distributions of characteristics and associations between characteristics and vaccination as non-immigrants, vaccination disparities would widen. Unmeasured and/or unknown variables (ie, the intercept) (influenza: 1.67 (95% CI -24.05 to 27.38); pneumococcal: 22.60 (95% CI -3.42 to 48.61)) had a substantial role in explaining disparities in both outcomes. These results suggest that immigrants have lower vaccination coverage despite being more likely to have traits associated with a higher likelihood of vaccination, some of which were more strongly associated with vaccination for immigrants. Commonly researched determinants of vaccination do not explain the lower vaccination coverage among older Canadian immigrants. Future research should investigate additional determinants, particularly societal and structural factors, that may shape vaccination decisions differently for immigrants, focusing on individual vaccine types. Such insights will inform the development of targeted interventions to address vaccine inequities in Canada.

PMID 43047962
阅读全文 →
PubMedJournal of nanobiotechnology2026-11-18

Baculovirus-based production of virus-like particles for avian influenza: development, immunogenicity, and cross-protection against H5 and H7 AIVs.

He Yanjuan Y, Dong Yajing Y, Kong Dexin D, Chen Huixin H et al.

The persistent threat of H5 and H7 highly pathogenic avian influenza (HPAI) necessitates effective broad-spectrum vaccines. This study systematically evaluated the immunogenicity and protective efficacy of H5N6 virus-like particle (H5N6-VLP) vaccine and subsequently developed a trivalent VLP vaccine (H5N6-H5N8-H7N9-VLP) using the baculovirus expression system (BEVS). Production of H5N6-VLP was optimized at a multiplicity of infection (MOI) of 0.1 to achieve efficient assembly. The H5N6-VLP vaccine induced potent immune responses in specific-pathogen-free (SPF) chickens, providing 100% protection against homologous H5N6-GD154 virus when the HA titer reached 9 log2. Compared with traditional inactivated vaccines, the H5N6-VLP vaccine induced faster humoral immune responses and higher CD8⁺ T cell proportions. The HI seroconversion rate was 30% on day 7 post-immunization (0% for inactivated vaccine), reached 100% by day 10, while it was only 80% on day 14 for the inactivated vaccine. Furthermore, the protective efficacy of the H5N6-VLP vaccine was associated with increased IFN‑γ expression and elevated proportions of B cells and CD8⁺ T cells. Although both vaccines provided complete homologous protection, the H5N6-VLP vaccine showed better cross-protection against the heterologous H5N1-D889 strain (70% vs. 40%). A delayed challenge experiment further demonstrated that the H5N6-VLP vaccine induced durable immunity, with HI titers remaining above the protective threshold and 100% protection against homologous challenge at 8 weeks post-immunization. Based on these findings, a trivalent H5N6-H5N8-H7N9-VLP vaccine was developed. The trivalent vaccine induced substantial antibody responses and provided complete protection against parental and circulating strains, with efficacy comparable to a commercial inactivated vaccine and no detectable antigenic interference between components. Our findings highlight the potential of the BEVS-derived H5N6-VLP vaccine, particularly its early antibody induction, which allows rapid flock protection during acute HPAI outbreaks, and its cross-reactivity against heterologous strains. Furthermore, the trivalent vaccine formulation extends the potential application of this VLP platform for broad-spectrum HPAI control.

PMID 43046102
阅读全文 →
PubMedCureus2026-11-18

Maternal Vaccine Receipt, Intentions, and Refusal Among Pregnant Women Attending Antenatal Care in Panama City: A Cross-Sectional Study.

Lucas Quintero Ana A, DeAntonio Rodrigo R, Escobar Luis L, Flores Luis Alberto LA et al.

Background/objectives Maternal vaccination surveys often combine willingness and receipt, potentially obscuring differences between these measures. We quantified self-reported vaccine receipt, intention without receipt, complete reported receipt, and refusal in an urban Panamanian convenience sample and examined their relationship with vaccination recommendation. Methods We analyzed an anonymous cross-sectional survey completed from March 26 to July 25, 2026, by 204 pregnant women aged 18 years or older recruited in health-related settings in Panama City. Self-reported receipt meant reporting at least one maternal vaccine during the current pregnancy. Intention without receipt meant planning at least one vaccine without reporting receipt of any specific vaccine. Complete reported receipt was the independent response "already received all," rather than verified completion of a vaccination schedule. Modified Poisson regression with robust variance estimated prevalence ratios (PRs). A secondary, post hoc evaluation examined six rating items without claiming formal questionnaire validation. Results The number of women who chose self-reported receipt was 128/204 (62.7%; exact 95% confidence interval (CI), 55.7-69.4), while the composite of receipt or intention was 190/204 (93.1%). Intention without receipt was reported by 62/204 (30.4%), complete reported receipt by 41/204 (20.1%), and refusal with coexisting receipt or intention by 92/204 (45.1%). Four participants reporting complete receipt did not report any vaccine-specific receipt. Refusal was reported for COVID-19 by 96/204 (47.1%), influenza by 11/204 (5.4%), tetanus, diphtheria, and acellular pertussis (Tdap) by 8/204 (3.9%), and respiratory syncytial virus (RSV) by 7/204 (3.4%). Receipt was reported by 126/172 (73.3%) participants with a vaccination recommendation versus 2/32 (6.2%) without one (adjusted PR, 11.28; 95% CI, 2.95-43.17). Three-item standardized Cronbach's alpha values were 0.699 and 0.728, with substantial ceiling effects and an unstable two-factor solution. Conclusions In this convenience sample, stated acceptance coexisted with the absence of reported receipt and vaccine-specific refusal. Recommendation was associated with receipt, but the estimate was imprecise and noncausal. These findings are not population estimates and support reporting recommendation, intention, receipt, and refusal separately. Intention without receipt does not establish subsequent failure to vaccinate.

PMID 43048589
阅读全文 →
PubMedJournal of virology2026-11-18

Structural basis of avian-to-human receptor-binding adaptation in H9Ny influenza A virus hemagglutinin.

Wang Min M, Zhao Chuankuo C, Peng Ruchao R, Bai Suran S et al.

The receptor-binding specificity of influenza A virus (IAV) hemagglutinin (HA) is a major determinant for viral host tropism, enabling interspecies transmission. The molecular determinants for receptor-binding properties of HAs vary among different IAV subtypes. In this study, we performed a comprehensive analysis on the receptor-binding determinants of IAV subtype H9 HA and found that the receptor-binding characteristics of H9 subtype influenza viruses have exhibited temporal variations over decades. Q226L (hydrophobicity switch) substitution in the 220-loop is the key determinant for H9 subtype HA to acquire human receptor-binding preference. The amino acid residues of the 130-loop greatly affect the binding of HA protein to canonical receptors. Organoid infection models demonstrate that all three representative viral strains could infect human bronchial epithelial organoids. These findings increase our understanding of the molecular determinants of receptor-binding properties of different HA subtypes and call for the surveillance and response to potential influenza outbreaks, or even epidemics/pandemics.IMPORTANCEInfluenza A virus (IAV) subtype H9 poses persistent zoonotic spillover risks due to its adaptive receptor-binding capacity, yet the molecular determinants remain incompletely defined. This study systematically characterizes the receptor-binding determinants of H9 hemagglutinin over decades of viral evolution and identifies two critical functional domains: the 220-loop residue Q226L substitution, which serves as the key mutation conferring human receptor-binding preference, and the 130-loop residues that predominantly modulate canonical receptor-binding affinity. Functional assays using human bronchial epithelial organoids further confirm the robust human infection ability of prevalent H9 viral strains. These findings clarify the molecular mechanisms underlying H9 IAV host tropism and adaptive evolution, provide critical theoretical evidence for targeted influenza surveillance and pandemic preparedness against emerging H9 influenza outbreaks.

PMID 43049477
阅读全文 →
PubMedSystematic reviews2026-11-18

Morbidity and mortality burden of seasonal influenza in sub-Saharan Africa: a systematic review and meta-analysis protocol.

Belizaire Marie Roseline Darnycka MRD, N'gattia Anderson Kouabenan AK, Chamla Dick Damas DD, Fall Ibrahima Socé IS et al.

Seasonal influenza poses a significant global health burden, responsible for substantial morbidity and mortality annually, particularly among high-risk populations such as the elderly, young children, pregnant women, and individuals with chronic illnesses. While the burden of influenza is well-documented in high-income countries, limited data exist for sub-Saharan African (SSA) countries, where fragile healthcare systems and underreporting obscure the true impact. Influenza exacerbates prevalent health conditions such as HIV, malaria, and malnutrition, further increasing its toll. The meta-analysis outlined in this protocol aims to systematically assess the morbidity and mortality burden of seasonal influenza in SSA countries, providing policymakers with critical insights to strengthen surveillance, prioritize at-risk populations, and inform vaccination strategies. This is a protocol for a planned systematic review and meta-analysis. This research will follow the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines, incorporating observational studies and surveillance reports published between August 2010 and December 2026. We will search major health databases, including MEDLINE (via PubMed), Embase, Scopus, Web of Science, and the Cochrane Library, as well as regional databases (African Index Medicus and the WHO Global Index Medicus) and grey literature sources (medRxiv and national health reports). Studies reporting laboratory-confirmed seasonal influenza cases from SSA countries will be included. A standardized form will be used for data extraction, capturing morbidity (prevalence, incidence, and hospitalization rates) and mortality (case-fatality rates and excess mortality rates) indicators. Pooled data will be analyzed using meta-analytic techniques, applying random-effects models to account for heterogeneity. Sensitivity analyses will address variations in case definitions, methodologies, and study quality across studies. Publication and language bias will be mitigated by including grey literature and applying no language restrictions. The completed review is expected to provide updated, pooled estimates of seasonal influenza-associated morbidity and mortality across SSA countries, stratified by age group, geographic subregion, and presence of comorbidities. These findings will support evidence-based policy decisions, including the strengthening of influenza surveillance systems and the prioritization of vaccination programs for high-risk populations in SSA countries. As this study involves secondary data from published literature, ethical approval is not required. Results will be disseminated via a peer-reviewed publication, conference presentations, and stakeholder meetings. Tailored reports will be shared with policymakers in SSA countries to translate findings into public health strategies, particularly to enhance surveillance and implement targeted vaccination programs. PROSPERO CRD42024617707.

PMID 43046258
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多influenza vaccine